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ABSTRACT
Christian, Lea Rajeshkumar, M.S., Department of Pharmacology and Toxicology,
Wright State University, 2021. Xeroderma Pigmentosum A Deficiency Results in
Increased Generation of Microvesicle Particles in Response to Ultraviolet B
Radiation.
Xeroderma Pigmentosum is a genetic disorder in which ability to repair DNA
damage such as from UV radiation is decreased. Nucleotide excision repair is
known for repairing DNA damage caused by UV radiation and XPA plays a major
role in recognizing and eliminating abnormal section of DNA. Therefore, XPA
deficiency decreases repair efficiency of DNA. Of note, XPA deficiency is linked
with photosensitivity. Microvesicle particles are membrane-bound particles which
are released into the extracellular environment in response to multiple stimuli
including the lipid Platelet activating factor (PAF). Previous studies have shown
that XPA deficiency can induce increase production of reactive oxygen species
and generates large amounts of PAF agonists produced non-enzymatically.
Hence, the present studies are designed to study if XPA deficiency induces higher
UVB-MVP release via PAF-R signaling pathway. Studies involving a XPA- deficient
keratinocyte cell-line were able to show that UVB irradiation can cause increase
MVP release. Similarly, XPA knockout (KO) mice generated increased MVP with
UVB irradiation both in skin as well as plasma in comparison to wild-type mice.
Increased production of cytokines (TNF-alpha and IL-6) were also seen in XPA KO
mice. However, absence of XPA did not affect MVP release when treated with
PAF-R agonist or phorbol ester TPA. Topical application of the acid
sphingomyelinase (aSMase) inhibitor imipramine was able to inhibit UVB induced
MVP release and pro-inflammatory cytokines. Likewise, genetically knocking down
aSMase affected MVP release by UVB irradiation in comparison to wild-type and
XPA KO mice. As MVP been involved in UVB signaling, inhibiting MVP release by
pharmacological means might be a novel therapeutic approach in photosensitive
conditions.
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CHAPTER I – INTRODUCTION
STATEMENT OF PROBLEM
Photosensitivity is a condition that could damage skin and cause skin cancer. It
has also shown to have a major role in pathophysiology of Lupus Erythematosus.
Although a lot of mechanisms and pathways have shown to contribute to severe
photosensitive conditions, therapeutic strategies which could be useful in
photosensitivity have not yet been determined. We believe that MVPs generated
by activation of ROS and PAF-R agonists is involved in causing severe
“photosensitive” responses such as redness, cytokines release and that these
responses might be inhibited by blocking acid sphingomyelinase.

SIGNIFICANCE OF RESEARCH
If enhanced MVPs are released by the lipid platelet activating factor pathway in
Xeroderma pigmentosum A deficient model then approaches that could block
MVPs release would be considered very useful in photosensitive conditions.

STATEMENT OF PURPOSE
The purpose of this study is to know if enhanced reactive oxygen species and
activation of PAF-R in XPA deficient models produce increased microvesicle
particles by UV radiation that can cause “photosensitive” response and by blocking
aSMase can reduce these responses in XPA deficient model.

LITERATURE
XERODERMA PIGMENTOSUM
Xeroderma Pigmentosum (XP) is a rare autosomal recessive condition (Kunisada,
2017). XP was first described by a physician through reporting a patient with dry
skin showing wrinkles and tremendous sensitivity to developing skin-based tumors
(JO, 2016). Later, the pathophysiology of the disease was recognized by intense
sun sensitivity which induces high risk for skin tumors. XPA is a DNA Damage
1

Recognition and Repair Factor in Nucleotide Excision Repair pathway (NER) (Yao,
2012).
NER is involved in repairing DNA damage caused by Ultraviolet Radiation. NER
pathway can be classified into two groups : Global Genome – Nucleotide Excision
Repair (GG-NER) and Transcription – Coupled Nucleotide Excision Repair (TCNER) (Marteijn, 2014). In the DNA damage system, GG-NER studies the whole
genome for damage, UVR – DNA damage binding protein is involved in
recognizing damage DNA while in TC-NER, DNA damage is indirectly recognized
by the stalling of RNA Polymerase II (Marteijn, 2014). In NER, nine major proteins
are involved and in that proteins which are responsible for causing disease are
XPA, XPB, XPC, XPD, XPE, XPF and XPG. XPA has a significant function in NER
pathway. XPA binds with damaged part of DNA and interacts with almost all
proteins and these proteins forms a complex to unwind the part of damage DNA
(Yao, 2012). Therefore, XPA deficiency leads to decrease efficiency in recognizing
and repairing UVB damage in DNA and thus linked to photosensitivity. UV-induced
autoimmune response has a pathogenic role in autoimmune disease such as
Lupus Erythematosus

(LE) (Lehmann P, 2009). Recent studies have

demonstrated that photosensitivity is the most common indicator in representing
LE (Lehmann P, 2009). Photosensitivity is considered as an early sign for lupus
spreading systemically.

ULTRAVIOLET RADIATION
Sun, which is the natural source of Ultraviolet Radiation emits UVA, UVB and UVC.
UVA penetrates deep into the dermis layer as it has the longest wavelength which
is 320 nm – 400nm. UVB has wavelength of 290nm – 320nm and it reaches to
epidermis layer of skin (Ullrich, 2005). UVC has wavelength of 100nm – 290nm,
UVC rays are the shortest waves which usually do not infiltrate the ozone layer.
Both UVA and UVB can cause skin damage, sunburn, aging and wrinkles. Even
though, UVA comprises 95% of the UV radiation that reaches the earth surface,
the role of UVB in causing non-melanoma skin cancer, the most common type of
skin cancer and immunosuppression is well known (Ullrich, 2005) (Yao, 2012). To
2

initiate immunosuppression different photoreceptors are being identified that can
absorb UV radiation, among them membrane lipid peroxidation and free radial
formation, trans- urocanic acid and epidermal DNA are considered as major
photoreceptors (Ullrich, 2005). In UV-induced immunosuppression, free radical
formation might play an important role. UV exposure can trigger activation of Src
tyrosine kinase. This leads to stimulation of downstream mediators such as Raf-1,
c-jun amino terminal protein kinase (JNK) and finally phosphorylation of regulatory
sites in the activation domain of c-jun leads to the NF-kB and AP-1 activation
(Ullrich, 2005). Studies have shown that antioxidants treatment blocks the UVinduced free radical damage.

PLATELET ACTIVATING FACTOR
Platelet Activating Factor, also known as acetyl-glyceryl-ether-phosphorylcholine
(AGEPC) or PAF, is a potent lipid mediator known to exert its effect in
inflammation, platelet aggregation and sensitivity through G-protein coupled
receptor, specifically called as platelet activating factor receptor (PAF-R) (Yao Y,
2009) . The PAF-receptor is known to expressed on variety of cells such as
neutrophils, mast cells, keratinocytes, fibroblasts, platelets, eosinophils (Damiani
E, 2016) (Yao Y, 2009). PAFR has many functions and a wide range of
pathophysiological effects.

Figure 1:

Structure of Platelet

Activating Factor (Damiani E,
2016)
Structure and Chemistry of PAF
PAF

is

a

1-alkyl-2-acetyl-sn-

glycero-3-phosphocholine.

PAF

includes three structural features
(Figure- 1) – 1. At sn-1 position, long chain alkyl group is present with an ether
bond 2. At sn-2 position, formation of glycerol through esterification of acetic acid
3

3. At sn-3 position, phosphocholine group is present (Damiani E, 2016). Alkyl
group at position 1, can have 12 to 18 carbon atoms in length, hence, signifies as
family of phospholipids.
Synthesis of PAF
PAF is synthesized both enzymatically and non-enzymatically. Enzymatic
synthesis includes both a remodeling and de-novo pathways. The remodeling
pathway consists of removal of fatty acids by phospholipase A2 (PLA2), mainly
cytosolic PLA2 as it is calcium-dependent and selective for arachidonic acid (AA)
and generates intermediate lyso-PC (LPC). Finally, PAF is produced through
attachment of acetyl group by LPC-acetyltransferases (LPCAT). Generally,
inflammatory cells use this pathway in response to cell-specific stimuli (Damiani E,
2016) (Shimizu, 2009). Cellular stimuli include induction of intracellular calcium
mobilization which leads to production of PAF (Travers JB, 1996). The de-novo
pathway consists of enzymes that can synthesize PAF from pre-existing neutral
lipid by adding phosphocholine. Non-enzymatic synthesis of PAF involves attack
of free radicals on the unsaturated fatty acids that can leads to oxidation process
and rearranging the bonds (Konger RL, 2008). This rearrangement produces
phospholipid reaction products that have potent PAFR activity. In comparison to
enzymatic PAF production, the generation of oxidized glycerophosphocholines
(Ox-GPC) is not controlled. Various factors might be responsible for generating
Ox-GPC such as reduced amount of antioxidant defenses and amounts of ROS
produced. Various environmental stressors have also shown to generate Ox-GPC
and they are, Ultraviolet B Radiation, cigarette smoke, radiation therapy, chronic
ethanol exposure (Marathe GK, 2005) (Sahu RP, 2013) (Yang L, 2010). Acute PAF
effects

include

inflammation

while,

chronic

PAF

effects

include

immunosuppression (Walterscheid JP, 2002).

EXTRACELLULAR VESICLES
Extracellular vesicles (EVs) were once considered as waste carriers, are now
recognized as their ability to exchange components between cells and because of
this property they might act as carriers for sending signals in normal homeostasis
4

or results in pathological developments (Van Niel G, 2018). EVs are heterogenous
cell-derived structures. Different subtypes of EV are: Microvesicle particles (MVPs)
which are also known as microparticles, have a size of 0.1~1µm, Exosomes,
smaller than MVPs are further divided into Large exosomes (90~120nm) and Small
exosomes (60~80nm). Recently, new EVs are being identified and classified
according to their size, Exomeres (< 50nm), Oncosomes (1~10µm) and
Migrasomes (0.5~3µm) (Chuo, 2018) (Figure-2). Exosomes are generated from
the micro vesicular bodies (MVB), they have a role in cell-cell communication as
they act as carrier of mRNAs and proteins. Oncosomes are known to be larger EV
and are produced from cancer cells by the process called budding. Migrasomes
and Exomeres biological function are yet to be identified (Chuo, 2018).

Figure 2: Schematic representation of different Extracellular vesicles
differentiated by their size and secretion pathways. (Chuo, 2018)
Microvesicle Particles
Microvesicle particles (MVPs) (ectosomes or microparticle or microvesicle) are
small membrane-bound particles which are released from the cell membrane via
budding. Initially, known to be cell debris, MVPs have now been considered to
have a role in keratinocyte cell signaling (Fahy K, 2017). The budding process
through which MVPs are released into extracellular environment include different
signaling pathways which involves upregulation of intracellular calcium
5

mobilization (Xiao X, 2015). Cellular and stimulus-dependent pathways are mainly
involved in MVPs release. For example, in endothelial cells, MVPs are released
due to p38 MAPK signaling (Norling, 2013) whereas, both p38 MAPK and Erk 1/2
pathways are involved in release of MVPs in THP-1 monocytes. Ceramides are
also known to produced MVPs release. The cell membrane consists of lipids,
cytokines, membrane receptors, adhesion molecules, enzymes and proteins and
when MVP are generated, they carry membrane contents into extracellular space
(Fahy K, 2017). Keratinocyte derived MVP have abundance of contents such as
pro-inflammatory cytokines (IL-6, IL-8, TNF-alpha, IFN-gamma), chemoattractants
(CXCL1, CXCL3, CXCL5 and CXCL6) and act as carrier of miRNAs (Shao S,
2020) (Kunisada, 2017). Because of these characteristics and functions, it is
possible that MVP might a regulator of inflammation and immunosuppression.
Previous studies have shown that the environmental and oxidative stressor UVB
can instigate production of reactive oxygen species (ROS) that can initiate the
production of PAF agonists, ultimately, leads to activation of PAF-R through
specific pathways. PAF-R activation, results in intracellular calcium mobilization,
stimulation of mitogen activating protein kinase and activation of NF-kB pathway.
Activation of PAF-R through abnormal production of ROS was also shown in
photosensitive model (Yao, 2012). MVPs are generated because of various stimuli
such as increase amount of intracellular calcium. The generation of MVPs by
activation of PAF-R can be blocked by antioxidants specific inhibitors (Fahy K,
2017) (Bihl JC, 2016). These studies indicate that, MVP release might be an
effector linking skin damage caused by environmental or oxidative stressor such
as UVB involving activation of PAF system. If this is the case, then, pharmacologic
or genetic approaches involving blocking of MVP release could be useful in
conditions such as photosensitivity.

6

PAF-R agonists

UVB

PAF-R

ROS
ASMASE AND
MAPK
INHIBITORS
ANTIOXIDANTS

Microvesicle
formation and
release

Figure 3: Model for UVB inducing Microvesicle via PAF-R signaling.
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CHAPTER II - HYPOTHESIS AND SPECIFIC AIMS
HYPOTHESIS:
It is hypothesized that Xeroderma Pigmentosum A deficiency induces increased
microvesicle particles release by Ultraviolet B Radiation via enhanced reactive
oxygen species production and increased generation of platelet activating factor
receptor agonists. Additionally, aSMase inhibitor reduces erythema, microvesicle
particles release and cytokines production in the XPA photosensitive murine
model.

SPECIFIC AIMS:
1. To compare UVB generated MVP in Human Keratinocytes cell line and
murine models that lacks XPA, which have been previously shown to
generate increase PAF-R agonists in response to UVB.
2. To determine the difference in MVP release by UVB that induces ROS in
comparison to CPAF/TPA that does not induce ROS between group that
lacks XPA and that which contain XPA.
3. To evaluate the role of aSMase and the effect of an aSMase inhibitor on
UVB induced MVP release in photosensitive murine model.

8

CHAPTER III – MATERIALS AND METHODS
CELLS AND CELL CULTURE :
Cells were grown as previously described (Bihl JC, 2016) in 10 cm Petri
dish using Dulbecco’s Modified Eagle Medium(DMEM) with high glucose
(GE Healthcare Life Sciences (Cytiva), HyClone, Cat No. SH30243.01)
10% FBS, 2mM glutamine, 100 U penicillin/ 0.1 mg/ml streptomycin, 0.25%
Trypsin-EDTA (1X) (Gibco, Ref no. 25200-056), Phosphate Buffered Saline
(FPBS) (1X) (PBS) 0.1 µM Sterile Filtered (Cytiva, HyClone Laboratories,
Cat. No. SH30256.01), Hank’s Balanced Salt Solution and 10mg/ml Bovine
serum albumin (HBSS+BSA).
Human keratinocyte- derived cell line (HaCaT) and XPA deficient HaCaT
cells (Kemp, 2016) were used in these studies. HaCaT cells, shows
characteristics of primary cultured skin keratinocytes in vitro were grown in
DMEM with high glucose under 5% CO2 and 19% O2 atmosphere,
temperature 37°C. Fresh medium was added every 2- 3 days. With cell
confluency of 80 to 90%, DMEM was discarded and washed with FPBS
twice and trypsinized the cells with 2ml of 0.25% trypsin-EDTA and kept in
incubator for 10 - 15 minutes.
In the 10 cm plate 8 ml fresh medium was added to make 10 ml and
triturated. Cell Count was done before adding cells into the new plates for
keeping equal cell numbers in the plates.

Trypan Blue Cell Viability:
After trypsinizing, 10 µL of medium and 10 µL of Trypan Blue dye was
prepared in the 1.5ml tube, and 10 uL of this solution was loaded in the slide
and slide was inserted, cell viability and cells were counted by Countess II
Automated Cell Counter.

9

Bringing Up cells from Liquid Nitrogen:
The vial of frozen cells was removed from liquid nitrogen and allowed to
warm up at room temperature and then directly poured into the plate
containing 10mL of fresh medium. Plate was kept in the incubator overnight
and on the next day, fresh medium was added to remove cells which were
not attached to the plate. Cells were checked every 2-3 days.

Treatments:
For the treatments, 3ml of HBSS+BSA was added into the plate after
washing with FPBS twice. The cells were then treated with different fluences
of UVB for fluences response curve. For vehicle, 0.1% Ethanol was added
in HBSS+BSA. The plates were than kept under UVB blue light for
calculated time points ( 1kJ/m2- 3 mins and 40 secs, 2.5 kJ/m2- 9 mins and
17 secs, 5kJ/m2- 18 mins and 33 secs). Concentration for CPAF was 100
µM stock, 3 µL from stock was added in 3 ml of HBSS+BSA to make the
final concentration of 100nM. TPA/PMA was prepared from the vial by first
adding 5 ml of ethanol to make the stock, 100 nM was considered as the
final concentration and was prepared in HBSS+BSA, 3 ml was added into
the plates. For no treatment group, 3 ml of HBSS+BSA was added into the
plate. Incubation time was considered four hours.

Microvesicle particles Isolation:
After the designated incubation time, supernatant was transferred from the
treatment plates into centrifuge tubes and centrifuged at 2,000 x g for 20
minutes in 4°C. After 20 minutes, supernatant was transferred into new 2
ml centrifuge tubes. It was again centrifuged at 20,000 x g for 70 minutes at
4℃. Supernatant was discarded gently, and tube was placed upside down
for 5 minutes so that it dries out completely. The pellet in the tube was
resuspended with 100 µL FPBS.

Microvesicle particles Detection:
10

The NanoSight 300 was used to measure MVP. The samples were diluted
with FPBS to remain within the threshold of the NanoSight NS300
instrument. After dilution, 700 µL was loaded by a syringe into the machine
and 3 videos for 30 seconds was calculated. The analysis was shown as
the mean of 3 tests.

Microvesicle particles Analysis:
The final particle concentration was calculated by considering dilution rate.
Fold change was calculated by normalizing treatment group to the no
treatment group. In the case of CPAF and TPA, fold change was calculated
by normalizing with vehicle. Mean ± S.E. was determined for each group
and analyzed on Minitab 19.

MICE:
Experiments was conducted between XPA knockout mice (XPA-deficient
mice), Smpd1 KO and C57BL/6 wild-type mice. Mice used were aged 1012 weeks. Mice were received ketamine/xylazine by weight to make them
sleep during the treatment. The backs of the mice were shaved, and they
received different fluences of UVB by calculated time points (1 kJ/m2, 2.5
kJ/m2, 5 kJ/m2). For CPAF TPA experiment, TPA (100 µM) was topically
applied. CPAF was prepared in the saline, the concentration was 250 ng
and 250 µL was injected. For vehicle, 90% DMSO:10% ethanol was
considered. For UVB + Imipramine experiment, 5 kJ/m2 UVB fluence was
received by shaved mice and 500 µM concentration of imipramine, 100 µL
was applied topically. Mice were housed under specific pathogen-free
conditions and all mice experiments were according to the protocol of the
experimental use of animals approved by Wright State University, School
of Medicine’s Laboratory Animal Care And Use Committee (LACUC).
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The designated time point for all the mice experiment was four hours. Skin
biopsy was taken for each mouse by biopsy punch (INTEGRA MILTEX,
5mm). Three biopsies were taken for MVP study, three biopsies for mRNA
and stored in RNA Later at 4℃ for overnight, next day it was transferred into
-20℃. One biopsy was taken for histology study, they were stored in 10%
Formalin at room temperature overnight and on next day, formalin solution
was removed and 70% ethanol was added. Blood was collected from each
mouse using syringe into heparin blood vacutainer for MVP detection in the
blood plasma.

Microvesicle particles Isolation:
•

Blood samples were centrifuged at 2000 x g for 20 minutes at 4℃.
The supernatant was designated plasma, and the plasma volume
was recorded, it was then transferred immediately into a 1.5 ml of
centrifuge tube, the tube was filled with 1.5 ml of FPBS and
centrifuged at 2000 x g for 20 minutes at 4℃. Supernatant was
directly poured into a new 1.5 ml tube. They were spun at 20,000 x
g for 10 minutes at 4℃. Supernatant was directly poured into 2 ml of
centrifuge tube. They were spin at 20,000 x g for 70 minutes at 4℃.
Supernatant was discarded and tubes were placed upside down for
at least 5 minutes for air drying. Pellet in the tube was re-suspended
with 100 µL of FPBS.

•

The skin biopsy was weighed and kept in 1.5 ml of centrifuge tube.
In the tubes, 0.5 ml of Collagenase/Dispase (final was added and
biopsy was cut finely with surgical scissors. Tubes were placed on
shaker at 37℃ overnight.
Next day, 1.5 ml of FPBS was added in each tube and centrifuged at
2000 x g for 20 minutes at 4℃. Supernatant was directly poured into
a new 1.5 ml tube. These tubes were centrifuged at 20,000 x g for
10 minutes at 4℃. Supernatant was directly poured into 2 ml of
centrifuge tube. They were spun at 20,000 x g for 70 minutes at 4℃.
12

Supernatant was discarded and tubes were placed upside down for
at least 5 minutes for air drying. Pellet in the tube was re-suspended
with 100 µL of FPBS.

Microvesicle particles Detection:
MVPs were detected by NanoSight NS300. The samples were diluted with FPBS
to remain within the threshold of the NanoSight NS300 instrument. After dilution,
700 µL was loaded by a syringe into the machine and 3 videos for 30 seconds was
calculated. The analysis was shown as the mean of 3 tests.
Erythema Measurements:
Erythema was measured with the help of the Mexameter MX 18. Mexameter was
placed on the back of skin and three readings was taken for each mouse before
UVB and after the designated incubation period. Differences were taken as a
measure of change in erythema.
RNA Isolation and Reverse Transcriptase Quantitative Polymerase Chain
Reaction (RT-qPCR):
RNA was isolated from the skin samples using RNeasy Plus Micro Kit (Cat No.
74034). First strand complementary DNA (cDNA) was generated using 100ng RNA
with a Reverse Transcription Kit using random primers (Bio-Rad). Reactions were
run in triplicate using Real Time PCR instrument using gene-specific primers. Ct
values were determined using the standard 2^-∆∆Ct method.
The following primer sequences were used mouse gapdh 5’-TGCACCACC
AACTGCTTAG–3’ (forward) and 5’-GATGCAGGGATGATGTTC-3’, mouse TNF
5’-TACTGAACTTCGGGGTGATTGGTCC-3’
CAGCCTTGTCCCTTGAAGAGAACC-3’

(forward)
(reverse),

CAGAATTGCCATCGTACAACTCTTTTCTCA-3’
AAGTGCATCGTTGTTCATACA-3’ (reverse).
13

mouse

(forward)

and
IL-6
and

5’5’5’-

STATISTICAL ANALYSIS:
Graphs were made using Microsoft Excel. Mean and significance was determined.
Comparison between groups was performed using One - Way Anova on Minitab
19. Data is shown as mean ± S.E of at least three experiments. If the P values
were less than 0.05 than the differences between sample were considered as
significant. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***).
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CHAPTER IV – RESULTS
UVB generates increased MVP release in HaCaT XPA deficient cells.
To determine MVP release in the human keratinocyte derived cell line HaCaT,
different fluences of UVB was considered as treatment. Cells were grown and
exposed with UVB (1kJ/m2, 2.5kJ/m2, 5kJ/m2). After the determined incubation
period, MVP release was analyzed. As shown in Figure- 4 and 5, with increase
fluences of UVB, MVP generation was also recorded higher with decreased
percentage cell viability. Also, MVP release was significantly higher in HaCaT XPA
deficient cells compared to HaCaT cells.
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Figure 4: UVB generates increased MVP release in HaCaT XPA deficient
cells. HaCaT cells and HaCaT XPA deficient cells received no treatment (NT),
1kJ/m2, UVB 2.5kJ/m2 and 5kJ/m2. After 4 hours, supernatant was removed
and MVP was measured. The numbers of MVP were normalized to cell count
and NT. Data are the mean ± S.E. fold change of at least three experiments.
Groups were compared using One-Way Anova. (P < 0.01) (P < 0.001) was
considered statistically significant. ** and *** denotes changes between NT and
UVB. $$ denotes changes between HaCaT and HaCaT XPA deficient cells.
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Figure 5: UVB irradiation decreases percentage cell viability in HaCaT and HaCaT XPA
deficient cells. After four hours of UVB treatment, cells were trypsinized and cell viability was
determined by Countess II Automated Cell Counter. (A) HaCaT cells and (B) HaCaT XPA deficient
cells, data are the mean ± S.E. of at least three experiments. Groups were compared using OneWay Anova and Tukey’s post-hoc test. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***) changes between
NT and UVB treatment group; no statistically significant difference between HaCaT XPA deficient
and HaCaT cells in decrease cell survival rate for UVB treatment. Red indicates for XPA deficient
cells.
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UVB irradiation generates greater erythema and MVPs release in XPA KO
mice
To confirm that increase fluences of UVB treatment might release significantly
higher MVP in XPA KO mice than WT mice, mice were anesthetized and their
shaved back were irradiated with UVB (1kJ/m2, 2.5kJ/m2, 5kJ/m2). After 4 hours of
designated period, skin biopsies were taken and blood plasma was collected from
each mouse for MVP analysis. To see if UVB irradiation can cause redness on the
back of mice, pictures were taken and erythema was measured with the help of
Mexameter before UVB treatment and after 4 hours of UVB treatment. As shown
in Figure-6, erythema measurements in XPA KO mice were higher than WT mice
after the UVB irradiation. MVP generation was increased significantly in skin tissue
and blood plasma (Figure-7). In skin tissue and blood plasma, MVP generation
was twice as high in XPA KO mice than WT mice with increasing UVB fluences.
As previously shown in XPA deficient murine model, UVB treatment increases
formation of Ox-GPC and PAF-R (Yao, 2012), because of higher levels of PAF-R,
MVP generation was highly increased in photosensitive model.
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Figure 6: UVB irradiation generates greater erythema response in XPA KO mice. Groups of
8-13 wild-type (C57BL/6) and XPA KO mice were either received NT, 1 kJ/m2 of UVB, 2.5 kJ/m2 of
UVB and 5 kJ/m2 of UVB to dorsal back skin and were analyzed four hours post-treatment. (A)
Representative photographs depicting erythema in Wildtype and XPA KO mice. (B) Picture of
Mexameter MX 18 showing an example for Erythema readings. (C) Before and four hours of postUVB treatment, erythema was measured with Mexameter. Data is shown as mean ± S.D. of fold
change in erythema readings. Groups were compared using One-Way Anova. P < 0.05 was
considered statistically significant. ($) denotes changes between wild-type and XPA KO mice. (*
and non-significant (ns)) denotes changes between no treatment and UVB.
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Figure 7: UVB irradiation generates increased MVP release in XPA KO mice. Groups of 8-13 wildtype (C57BL/6) and XPA KO mice were either treated with NT, 1 kJ/m2 of UVB, 2.5 kJ/m2 of UVB and
5 kJ/m2 of UVB to dorsal back skin. Four hours post-treatment, (A). Triplicate skin biopsies were
obtained, weighed and MVP was measured. (B). Plasma was obtained and MVP was measured. Data
are the mean ± S.E. fold change of MVP count. Groups were compared using One-Way Anova and
Tukey’s post-hoc test. Differences in samples were considered significant if the P value is less than
0.05. P < 0.05 ($) changes between WT and XPA KO mice; P < 0.05 (*) P < 0.01 (**) changes between
NT and UVB treatment.
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Figure 8: UVB irradiation generates increase pro-inflammatory cytokines in XPA KO
mice. RNA was isolated from skin biopsies of wild-type and XPA KO mice and RT-qPCR
was performed. Data are the mean ± S.E. relative mRNA expression of (A) TNF-alpha
and (B) IL-6. Groups were compared using One-Way Anova and Tukey’s post-hoc test.
Differences in samples were considered significant if the P value is less than 0.05. P <
0.05 ($) changes between WT and XPA KO mice; P < 0.05 (*) P < 0.01 (**) changes
between NT and UVB.
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UVB irradiation generates increase pro-inflammatory cytokines in XPA KO
mice.
RNA was isolated from skin biopsy and RT-qPCR was performed for TNF and IL6. Environmental stressor UVB, causes upregulation of TNF and IL-6 in WT and
XPA KO mice (Figure-8). However, inflammatory cytokines were more highly
expressed in photosensitive mice (XPA KO ) as compared to WT mice. These data
suggest that MVP released in extracellular environment might be responsible in
upregulation of cytokines. Hence, more MVP release result in more cytokine
disbalance in the environment. Thus, MVP might act as a regulator for causing
inflammation in photosensitive conditions.

CPAF/TPA treatment does not result in differences in MVP release in
HaCaT XPA deficient cells vs HaCaT cells.
To see whether ROS production is involved in the increased generation of MVP,
HaCaT cells and HaCaT XPA deficient cells were grown and treated with UVB
(1kJ/m2, 5kJ/m2), CPAF 100nM (Carbamyl-platelet-activating factor (CPAF) an
analogue of PAF. CPAF acts as PAF agonist by increasing free intracellular
calcium levels (Travers JB L. Q., 1992), TPA/PMA 100nM (tetradecanoyl phorbol
acetate (TPA) known for stimulation of MAPK), Vehicle (HBSS+BSA:EtOH) and
control was considered. After 4 hours of incubation period, MVP was isolated and
analyzed. As shown in Figure-9, HaCaT cells or HaCaT XPA deficient cells, treated
with CPAF or TPA (agents which do not induce ROS production) were showing no
difference in MVP release, while UVB (agent that induce ROS) treated HaCaT XPA
deficient cells were able to generate MVP higher than HaCaT cells. Also, UVB
treated cells have shown reduced cell survival percentage as compared to CPAF
TPA treated cells (Figure-10).

22

6

HaCaT cells
HaCaT XPA deficient cells

$$
***

MVP Concentration
(Fold Change)

5

ns
_________
**

$
***

4

***
**

ns
_________
*** ***

3
*
2

1

0
No
Treatment

Vehicle

1
______UVB

5

CPAF

TPA

(kJ/m2)______

Figure 9: CPAF/TPA treatment does not result in differences in MVP release in HaCaT
XPA deficient cells vs. HaCaT cells. HaCaT cells and HaCaT XPA deficient cells were either
received No Treatment, Vehicle (0.1% EtOH), 1kJ/m2 UVB, 2.5kJ/m2 UVB, CPAF 100nM and
TPA 100nM. Supernatant was removed four hours post-treatment and MVP was quantitated
and normalized to cell counts and no treatment. Data are the mean ± S.E. fold change of
MVP from at least three separate experiments. Groups were compared using One-Way
Anova and Tukey’s post-hoc test. Differences in samples were considered significant if the P
value is less than 0.05. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***) and non-significant (ns)
changes between No Treatment and UVB; Vehicle and CPAF , TPA treatment. P < 0.05 ($),
P < 0.01 ($$) and non-significant (ns) changes between HaCaT and HaCaT XPA deficient
cells.
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Figure 10: Effect of various treatments on percentage cell viability of HaCaT and
HaCaT XPA deficient cell lines. After the treatments shown in figure 9, cells were trypsinized
and cell viability was determined with Countess II. (A) HaCaT cells and (B) HaCaT XPA
deficient cells, data are the mean ± S.E. of at least three experiments. Groups were compared
using One-Way Anova and Tukey’s post-hoc test. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***)
and nonsignificant (ns) changes between No Treatment and UVB; Vehicle and CPAF 100 nM
or TPA 100 nM in HaCaT and HaCaT XPA deficient cells.
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Figure 11: CPAF/TPA treatment does not result in differences in MVP release in Wild-type vs. XPA
KO mice. Groups of 7-9 Wild-type and XPA KO mice have their backs shaved and treated with 90% DMSO
(Vehicle), TPA 100 µM topically and injected CPAF 250ng i.p. Four hours post-treatment, (A). Triplicate skin
biopsies were obtained and MVP was measured.(B). Plasma was obtained and MVP was measured. Data
are the mean ± S.E. fold change of MVP. Groups were compared using One-Way Anova and Tukey’s posthoc test. Differences in samples were considered significant if the P value is less than 0.05. P < 0.05 (*), P
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< 0.01 (**), P < 0.001 (***) between Vehicle and CPAF/TPA and non-significant (ns) changes between WT
and XPA KO mice.

CPAF/TPA treatment does not result in differences in MVP release in XPA
KO mice vs WT mice.
To confirm if there is a difference in MVP generation between WT and XPA KO
mice when treated with PAF agonist (CPAF) or TPA that does not generate MVP
by stimulating ROS, shaved back of anesthetized mice were injected with 250
microL of CPAF (250 ng) i.p. and 100 microL of TPA (100 microM) was applied
topically on shaved back of mice and for vehicle (90% DMSO) was also applied
topically. After 4 hours, skin biopsy was taken and blood plasma was collected and
MVP was analyzed. In skin tissue or blood plasma, there was no difference in MVP
release between WT and XPA KO mice (Figure-11). These data confirm that,
model that lacks XPA and the one that does not lack XPA, produce UVB – MVP
by inducing ROS and CPAF or TPA directly activates PAF-R or stimulate other
pathways to generate MVP without inducing ROS. Hence, ROS production is
involved in generation of MVP release by UVB and irregular ROS production can
cause increase microvesicle release in photosensitive condition.

Acid sphingomyelinase Inhibitor imipramine reduces UVB induced
erythema and MVP release in XPA KO mice.
Acid Sphingomyelinase (aSMase) is also known to generate MVP via activation of
PAF-R. Inhibitors of aSMase might be a novel strategy to block UVB-MVP release
in XPA deficient model. Imipramine (a known aSMase inhibitor) has shown to have
an inhibitory effect on MVP generation. To see whether Imipramine can block UVBMVP release in XPA deficient murine model, anesthetized WT and XPA deficient
mice were irradiated with 5 kJ/m2 UVB and immediately after UVB treatment, 100
microL of imipramine (500 microM) was applied topically on the shaved back of
26

mice. To check the inhibition of MVP release by Imipramine, mice were also
treated with only UVB fluences and to make sure if Imipramine alone is not causing
MVP generation, imipramine alone mice group was also considered and lastly,
control group was considered that does not received UVB or imipramine. Erythema
was measured by Mexameter before treatment and after 4 hours of treatment. Skin
biopsy and blood plasma was collected and MVP was analyzed. As shown in
Figure-12, UVB treatment alone showed greater erythema which was reduced
significantly after applying imipramine topically. aSMase inhibitor imipramine was
able to block MVP release after the UVB treatment in photosensitive mice and Wild
Type mice (Figure-13). However, UVB treatment alone group was showing 5-to-8fold increase in MVP generation in XPA KO mice than WT mice (Figure-13).
Imipramine alone has minimal effect on generation of MVP.

Acid Sphingomyelinase Inhibitor reduces UVB induced pro-inflammatory
cytokines in XPA KO mice.
To confirm if imipramine can reduce pro-inflammatory cytokine production induced
by UVB, RNA was isolated from skin biopsy and RT-qPCR was performed. TNF
and IL-6 were upregulated by UVB were significantly downregulated by topically
applied Imipramine (Figure- 14). These data show that, pharmacologic approach
to block MVP release might be a novel strategy in the treatment of photosensitivity.
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Figure 12: Acid Sphingomyelinase inhibitor imipramine reduces UVB induced erythema
in XPA KO mice. Group of 6-8 wild-type and XPA KO mice were either received no treatment
(NT), imipramine 500 µM only, 5kJ/m2 UVB, UVB + imipramine 500 µM. (A) Representative
photographs showing comparison of redness on shaved back of WT and XPA KO mice
between UVB treatment group and UVB + imipramine treatment group. (B) Before and after
four hours of post-treatment erythema was measured with Mexameter MX 18. Data is shown
as mean ± S.E. of fold change in erythema measurements. P < 0.05 (*) between NT and UVB.
P < 0.01 ($$) changes between UVB only and UVB + imipramine in both Wildtype and XPA
KO mice and P < 0.05 ($) between UVB group in WT and XPA KO mice.
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Figure 13: Acid Sphingomyelinase inhibitor imipramine inhibits UVB
induced MVP release in

XPA KO mice. Groups of 6-8 wild-type and XPA KO mice were either received no treatment (NT),
imipramine 500 µM only, 5KJ/m2 UVB, UVB + imipramine 500 µM and were analyzed after 4 hours of
post-treatment. (A) Triplicate skin biopsies were obtained and MVP was measured. (B) Plasma was
obtained and MVP was measured. Data is shown as mean ± S.E. of fold change in MVP count. P <
0.05 (*), P < 0.01 (**) between NT and UVB. P < 0.05 ($), P < 0.01 ($$) changes between UVB only
and UVB + imipramine in both WT and XPA KO mice and P < 0.05 ($) between UVB group in WT and
XPA KO mice.
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Figure 14: Acid Sphingomyelinase inhibitor imipramine inhibits UVB induced proinflammatory cytokines in XPA KO mice. RNA was isolated from skin biopsies of Wildtype
and XPA KO mice and RT-qPCR was performed. Data are the mean ± S.E. relative mRNA
expression of (A) TNF-alpha and (B) IL-6. Groups were compared using One-Way Anova.
Differences in samples were considered significant if the P value was less than 0.05. P < 0.05
(*) between NT and UVB. P < 0.05 ($) changes between UVB only and UVB + imipramine in
both WT and XPA KO mice and P < 0.05 ($) between UVB group in WT and XPA KO mice.
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Role of Acid Sphingomyelinase in UVB induced inflammatory response.
To see whether genetically knocking down the aSMase in mice can be able to
inhibit UVB induced MVP release, shaved back of Smpd1 KO mice along with WT
and XPA KO mice was irradiated with 5 kJ/m2 of UVB. After four hours of UVB
treatment, erythema was measured and MVP was isolated and detected in skin
tissue and plasma. Erythema readings were not much affected with UVB irradiation
in comparison to no treatment group in Smpd1 KO mice, however, erythema was
higher in WT and XPA KO mice with UVB treatment compared to no treatment
(Figure-15(A)). UVB-MVP release was reduced in Smpd1 KO mice than the no
treatment group both in skin tissue and blood plasma (Figure-15(B and C)).
Together, these data indicate that aSMase is required for UVB induced MVP
release in either WT or XPA KO mice and by inhibiting aSMase by its inhibitor
imipramine or genetically knocking down aSMase can decrease the generation of
MVP in XPA KO mice.
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Figure 15: Role of Acid Sphingomyelinase in UVB induced erythema, MVP
release and cytokines production. Groups of 7-9 wild-type (WT), Smpd1 KO and
XPA KO mice received either no treatment (NT) or 5 kJ/m2 of UVB. (A) Before and after
four hours of post treatment erythema was measured by Mexameter MX 18. Data is
shown as mean ± S.D. of fold change in erythema measurements. (B) Triplicate skin
biopsies were obtained and MVP was measured. (C) Plasma was obtained and MVP
was measured. Data is shown as mean ± S.E. of fold change in MVP. RNA was isolated
from skin biopsies of Wildtype, Smpd1 KO and XPA KO mice and RT-qPCR was
performed. Data are the mean ± S.E. relative mRNA expression of (D) TNF-alpha and
(E) IL-6. P < 0.05 (*), P < 0.01 (**), non-significant (ns) changes between NT and UVB
in WT, Smpd1 KO and XPA KO mice. P < 0.05 ($), P < 0.01 ($$), P < 0.001 ($$$)
between WT UVB group and Smpd1 KO UVB; XPA KO UVB treatment group.
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CHAPTER V – DISCUSSION
Xeroderma Pigmentosum A protein forms a complex with other proteins involved
in Nucleotide Excision Repair and this protein complex removes the damage
section of DNA (Yao, 2012). XPA deficiency can cause severe sensitivity to
Ultraviolet Radiation and increase risk of multiple skin cancer (Kunisada, 2017).
However, the exact mechanism through which exaggerated redness and
inflammation occurs in XPA deficiency by UV radiation is not well elucidated.
Previously, it has been shown that PAF a well-known mediator for UV induced
inflammation and immunosuppression and Ox-GPCs and PAF-R agonists are
elevated in and thus could act as a mediator in photosensitivity associated with
XPA deficiency (Yao, 2012) (Damiani E, 2016). The present studies involve
exaggerated release of microvesicle particles in response to Ultraviolet B
Radiation associated with XPA deficiency. This study investigated that release of
microvesicle particles was increased and pro-inflammatory cytokines were also
highly upregulated after UVB irradiation in XPA KO in comparison WT group both
in vitro and in vivo which were inhibited by acid sphingomyelinase inhibitor
imipramine. To better study effects such as inflammation followed by cell death of
UVB irradiation on human skin, we used human immortalized keratinocytes cell
line (HaCaT) where shRNA was used for silencing XPA gene (Kemp, 2016). From
fluences response studies (Figure-4), 5 kJ/m2 UVB light was seen to produce
extreme effects on HaCaT cell line and with increasing UVB irradiation,
microvesicle generation was increased significantly in HaCaT XPA deficient cells
compared to control HaCaT cells (Figure-4). These toxic effects might be because
of UVB induces cytokines/chemokines (IL-6, IL-8, TNF-alpha, Interferon gamma)
production

in human keratinocytes (Yoshizumi M, 2008). UVB irradiation

generates inflammatory responses in XPA knockout mice by activating certain
pathways and genes such as chemokine signaling pathway (CXCL14, CXCL1,
CXCL2), cytokine and inflammatory response pathway (CXCL1, IL-6 and tumor
necrosis factor) (Yao, 2012) (Kunisada, 2017). Our study confirms that UVB
irradiation on the shaved back of wild-type and XPA knockout mice generates
inflammatory response (Figure-6,). However, XPA knockout mice have shown to
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produce increased inflammatory response by generating increase microvesicle
and cytokines release (Figure-7,8). This response was due to increase production
of reactive oxygen species and PAF agonists. To demonstrate if UVB is involved
in the increased generation of MVP in XPA KO group by inducing higher production
of ROS, CPAF/TPA treatment was considered as CPAF/TPA produces MVP by
not inducing ROS as they directly act on activating PAF-R or by triggering different
pathways in the process to generate MVP release. Our data was able to show that
there was no significant difference between WT and XPA KO group in MVP release
with CPAF/TPA treatment (Figure- 9,11).
Ceramide is known to be a key regulator for releasing MVP through lipid pathway
and platelet activating factor is considered to be contributing to generating Acid
Sphingomyelinase dependent ceramide (Goñi FM, 2014). Here, we show that
either using aSMase inhibitor or by genetically knocking down Smpd1 gene (acid
sphingomyelinase is the protein encoded by Smpd1 gene) affects the UVB induced
production of MVP release and production of pro-inflammatory cytokines (Figure12-15).
In summary, the present studies indicate that UVB induces increased generation
of MVP in XPA deficient model both in vitro as well as in vivo by trigging production
of ROS and PAF-R agonists that can be inhibited by aSMase inhibitor or
genetically knocking down Smpd1 gene.
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CHAPTER VI – FUTURE STUDIES
The significance of these studies is to demonstrate role of MVP release in
photosensitive condition and providing pharmacologic and genetic approach to
inhibit MVP release. If future studies include crossing XPA KO mice with Smpd1
KO (XPA -/- x Smpd1 -/-) that will confirm the role of aSMase in UVB induced
generation of MVP in vivo. These studies, involving MVP and aSMase might be
considered as an innovative findings for Lupus Erythematosus where
photosensitivity has considered to be major symptom in developing lupus.
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CHAPTER VII – CONCLUSION
These

studies

demonstrate

that

UVB

irradiation

induces

exaggerated

inflammatory responses in XPA KO model. These “photosensitive” responses
include enhanced erythema, cytokine expression which might be because of
increase ROS production and PAF-R agonists that releases MVP by stimulating
aSMase. However, these inflammatory responses can be inhibited by topical
application of aSMase inhibitor imipramine pharmacologically or by genetically
knocking down aSMase. These studies could be considered as groundbreaking
research for photosensitive conditions.
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